Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1136/annrheumdis-2020-218296

http://scihub22266oqcxt.onion/10.1136/annrheumdis-2020-218296
suck pdf from google scholar
32796045!?!32796045

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32796045&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid32796045      Ann+Rheum+Dis 2020 ; 79 (12): 1544-1549
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study #MMPMID32796045
  • Pablos JL; Galindo M; Carmona L; Lledo A; Retuerto M; Blanco R; Gonzalez-Gay MA; Martinez-Lopez D; Castrejon I; Alvaro-Gracia JM; Fernandez Fernandez D; Mera-Varela A; Manrique-Arija S; Mena Vazquez N; Fernandez-Nebro A
  • Ann Rheum Dis 2020[Dec]; 79 (12): 1544-1549 PMID32796045show ga
  • OBJECTIVES: The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a matched control cohort to identify potential risk factors for severe illness. METHODS: In this comparative cohort study, we identified hospital PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or connective tissue diseases (CTDs). Non-rheumatic controls were randomly sampled 1:1 and matched by age, sex and PCR date. The main outcome was severe COVID-19, defined as death, invasive ventilation, intensive care unit admission or serious complications. We assessed the association between the outcome and the potential prognostic variables, adjusted by COVID-19 treatment, using logistic regression. RESULTS: The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age was 63 (IQR 53-78) years and male sex 41% in both cohorts. Rheumatic diseases were IA (60%) and CTD (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID-19 was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male sex and previous comorbidity (obesity, diabetes, hypertension, cardiovascular or lung disease) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID-19 were increased age (OR 4.83; 95% CI 2.78 to 8.36), male sex (1.93; CI 1.21 to 3.07) and having a CTD (OR 1.82; CI 1.00 to 3.30). CONCLUSION: In hospitalised patients with chronic inflammatory rheumatic diseases, having a CTD but not IA nor previous immunosuppressive therapies was associated with severe COVID-19.
  • |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH]
  • |Age Factors[MESH]
  • |Aged[MESH]
  • |Alanine/analogs & derivatives/therapeutic use[MESH]
  • |Antiviral Agents/*therapeutic use[MESH]
  • |Arthritis, Psoriatic/complications/drug therapy/epidemiology[MESH]
  • |Arthritis, Rheumatoid/complications/*drug therapy/epidemiology[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |Cardiovascular Diseases/epidemiology[MESH]
  • |Case-Control Studies[MESH]
  • |Cohort Studies[MESH]
  • |Comorbidity[MESH]
  • |Connective Tissue Diseases/complications/*drug therapy/epidemiology[MESH]
  • |Coronavirus Infections/complications/*drug therapy/epidemiology[MESH]
  • |Drug Combinations[MESH]
  • |Female[MESH]
  • |Glucocorticoids/therapeutic use[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/therapeutic use[MESH]
  • |Immunosuppressive Agents/*therapeutic use[MESH]
  • |Logistic Models[MESH]
  • |Lopinavir/therapeutic use[MESH]
  • |Lupus Erythematosus, Systemic/complications/drug therapy/epidemiology[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Obesity/epidemiology[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/complications/*drug therapy/epidemiology[MESH]
  • |Polymyalgia Rheumatica/complications/drug therapy/epidemiology[MESH]
  • |Prognosis[MESH]
  • |Rheumatic Diseases/complications/drug therapy/epidemiology[MESH]
  • |Risk Factors[MESH]
  • |Ritonavir/therapeutic use[MESH]
  • |SARS-CoV-2[MESH]
  • |Severity of Illness Index[MESH]
  • |Sex Factors[MESH]
  • |Sjogren's Syndrome/complications/drug therapy/epidemiology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box